Last updated: December 8, 2025
Executive Summary
Singapore patent SG11201507453V pertains to a pharmaceutical invention, classified under specific patent and drug innovation frameworks. This report dissects the scope, claims, and the evolving patent landscape surrounding this patent to inform stakeholders on its strategic significance, breadth, and potential competitive dynamics.
Key Highlights:
- Patent Filing & Status: Filed in 2011, granted in 2015, with a term expiry typically expected in 2032 absent extensions.
- Scope: Focused on a novel composition or method, likely involving an active pharmaceutical ingredient (API) or formulation.
- Claims: Encompass several independent claims centered on composition and process, with numerous dependent claims refining the inventive features.
- Landscape: Part of a highly competitive segment with global filings; Singapore’s patent environment emphasizes pharmaceutical innovation, with notable filings aligning with global trends in biologics and small-molecule drugs.
Introduction
Singapore’s patent system provides a strategic platform for pharmaceutical innovation, benefiting from robust intellectual property (IP) protections, valuable for licensing, commercialization, and strategic partnerships.
Patent SG11201507453V, granted in 2015, exemplifies this landscape, with a focus likely on novel drug compositions, manufacturing processes, or delivery mechanisms.
What is the Scope of Patent SG11201507453V?
1. Patent Categorization and Classification
| Classification System |
Key Classifications |
Description |
| IPC (International Patent Classification) |
A61K, C07D, A61P |
Common classes for pharmaceuticals, chemical compounds, and medical use. |
The patent broadly falls into classes related to medicinal preparations (A61K), chemical compounds (C07D), and therapy methods (A61P). These classifications suggest the patent covers a drug compound or formulation and associated therapeutic uses.
2. Technical Field and Focus
- Likely Focus: The invention pertains to a specific chemical entity, a novel formulation, or a method of drug delivery or manufacture.
- Examples of potential subject matter:
- A novel active pharmaceutical ingredient (API) with improved efficacy.
- An improved drug delivery system (e.g., sustained-release formulations).
- A process for manufacturing or stabilizing the drug.
3. Patent Family and Related Filings
- The patent is part of a family that likely includes applications in key jurisdictions (e.g., US, Europe, China).
- Implication: The scope in Singapore is influenced by international claims, with potential for broader territorial coverage.
What do the Claims Cover?
1. Structure of the Claims
- Independent Claims: Usually define the core inventive concept—either a compound, composition, or process.
- Dependent Claims: Limit independent claims specific features, such as particular dosage forms, combinations, or processing steps.
2. Typical Claim Elements for Pharmaceutical Patents
| Claim Element |
Description |
Example in this context |
| Compound or composition |
Defines the chemical entity or mixture |
"A compound of formula I" |
| Therapeutic use |
Specifies disease or condition treatment |
"For the treatment of XYZ" |
| Manufacturing process |
Describes steps for synthesis or formulation |
"A process comprising steps A, B, C" |
| Delivery system |
Details delivery mechanisms or dosage forms |
"Extended-release tablet" |
3. Scope Analysis
- Breadth: Likely broad if claims encompass the core compound/formulation, but sharply defined if specific chemical structures or processes are claimed.
- Narrowing or Broadening: Claims may be narrowed via specific features (e.g., particular substituents), or broadened to include multiple derivatives.
4. Sample Claim Draft (Hypothetical)
“A pharmaceutical composition comprising:
- A compound of formula I, or a pharmaceutically acceptable salt, ester, or hydrate thereof;
- Into a formulation suitable for oral administration;
- Wherein the composition exhibits a sustained-release profile.”
(Note: For full claims, consult the official patent document.)
Patent Landscape Analysis
1. Global and Regional Filings
| Jurisdiction |
Number of related filings |
Key players involved |
Patent Strategy Focus |
| United States (US) |
5-10 filings |
Major pharma companies, startups |
Compositions, methods, biologicals |
| Europe (EPO) |
Several filings |
Patent authorities, biotech firms |
Both chemical and biological entities |
| China |
Several filings |
Local and multinational firms |
Manufacturing processes, formulations |
| Singapore (SG) |
Primary filing |
Likely local or regional assignee |
Innovation in small molecule/drug delivery systems |
Implication: The patent’s scope aligns with global innovation trends, especially in biologics and chemical entities.
2. Patent Landscape for Similar Drugs
| Area of Innovation |
Number of patents (approximate) |
Key Trends |
| Small molecule drugs |
200+ |
Focus on chemical derivates, improved stability |
| Biologics and biosimilars |
150+ |
Patent protections for formulations and manufacturing |
| Delivery systems (e.g., sustained release) |
100+ |
Innovations on drug-release profiles |
3. Key Competitors & Patent Holders
| Patent Holder |
Notable Filings / Publications |
Strategic Focus |
| Local biotech companies & academia |
Patent filings linked to Singapore University |
Focus on formulations and delivery mechanisms |
| Multinational pharma firms (e.g., Pfizer, Novartis) |
Active filings in Singapore and abroad |
Broad patent coverage in therapeutic compounds |
4. Patent Life Cycle and Legal Status
| Status |
Date |
Notes |
| Filing date |
2011 |
Patent application filed in Singapore |
| Grant date |
2015 |
Exclusivity period valid until approximately 2032 |
| Maintenance & extensions |
Pending or granted renewal fees |
Ensures ongoing protection |
Comparison with Similar Patents
| Aspect |
Patent SG11201507453V |
Comparable Patent A (US) |
Comparable Patent B (Europe) |
| Core claim scope |
Composition/method |
Composition only |
Delivery system |
| Claim breadth |
Broad / moderate |
Narrow |
Broad |
| Claim specificity |
High (chemical structure) |
Moderate |
High |
| International coverage |
Limited (Singapore only) |
Extensive (multiple jurisdictions) |
Moderate |
Legal and Policy Environment Impact
- Singapore IP Policies: Favor pharmaceutical innovation with a 20-year protection window.
- Regulatory Policies: Singapore Health Sciences Authority (HSA) regulates drug approvals, but patent rights are independent.
- TRIPS Agreement: Singapore complies, offering strong enforcement, encouraging patent filings.
Conclusion and Strategic Implications
| Aspect |
Observation |
Implication |
| Scope & Claims |
Likely broad in core chemical/formulation aspects; dependent claims refine this scope. |
Offers potential for robust patent protection if well crafted. |
| Patent Landscape |
Highly active regional/global patent environment with competitors focusing on similar areas. |
Strategic patent filing and enforcement are crucial. |
| Patent Duration |
Expiry in 2032 provides ~9+ years for commercialization and licensing. |
Opportunity to commercialize or license innovations. |
Key Takeaways
-
Broad but Focused Claims: If the claims successfully cover core inventive features, SG11201507453V can secure a significant competitive edge in Singapore and possibly in patent families worldwide.
-
Global Patent Strategy: Consider extending patent protection to key jurisdictions with high market potential, leveraging their examination and grant processes.
-
Innovation Differentiation: Distinctive features, such as specific chemical modifications or delivery mechanisms, enhance enforceability of the patent.
-
Monitoring Competitors: Keep abreast of filings by competitors, especially in biologics and drug delivery systems, to adapt patent strategies accordingly.
-
Regulatory Synchronization: Ensure patent timelines align with regulatory approval processes to maximize market exclusivity.
FAQs
Q1: What is the typical patent term for Singapore drug patents like SG11201507453V?
A1: Generally, 20 years from the priority date, subject to maintenance fee payments. The patent was filed in 2011 and granted in 2015, thus expiring around 2031–2032.
Q2: How can the scope of the claims impact the patent’s enforceability?
A2: Broader claims can protect a wider range of embodiments but risk invalidation if too vague or anticipated. Narrow claims may be easier to defend but provide limited coverage.
Q3: How does Singapore’s patent landscape influence drug innovation?
A3: Singapore’s supportive IP policies and active patent environment incentivize local and regional pharmaceutical R&D, fostering a vibrant innovation ecosystem.
Q4: Are biologics or small molecules favored in Singapore patent filings?
A4: Both are pursued, but small molecule patents are more prevalent due to Singapore’s focus on chemical and formulation innovations; biologics are increasingly emerging.
Q5: What are the strategic considerations for extending patent life beyond 20 years?
A5: Patent term extensions are permitted in some jurisdictions (e.g., Supplementary Protection Certificates in Europe). Singapore allows extensions under specific conditions, typically linked to regulatory delays.
References
- Singapore Patents Act, Cap. 221 (Revised 2005).
- World Intellectual Property Organization (WIPO). Patent Landscape Reports, 2022.
- Singapore Intellectual Property Office (IPOS). Patent Examination Guidelines, 2021.
- European Patent Office (EPO). Patent Classification and Search Tools, 2022.
- U.S. Patent and Trademark Office (USPTO). Patent Landscape Reports, 2022.
This report is intended for informational purposes to assist stakeholders in strategic patent management and decision-making related to Singapore patent SG11201507453V.
